← back to search
Ralph K. Lindemann
Xenetic Biosciences (United Kingdom) · GB
Area of research
Molecular Biology · Oncology
Research interest
Research interests include PARP inhibition in cancer therapy, Histone Deacetylase Inhibitors Research, Protein Degradation and Inhibitors, and PI3K/AKT/mTOR signaling in cancer.
h-index
22
citations
2,818
works
64
NIH funding
—
primary concept
—
email
✉ Find email ↗
Recent publications
Extrachromosomal DNA micronucleation constrains tumour fitness and improves patient survival
bioRxiv (Cold Spring Harbor Laboratory)
2025
cited by
5
position: middle
doi
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
JCI Insight
2022
cited by
17
position: middle
doi
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- <i>Myc</i> Lymphoma by Restoring Oncogene-Induced Senescence
Cancer Discovery
2012
cited by
62
position: middle
doi
Grants
No grants ingested yet.
Frequent collaborators
Katherine M. Hannan
· Acton Institute
1
papers (2012–2012)
Christoph Schell
· Rockefeller University
1
papers (2022–2022)
Philipp Seidel
· Carl Zeiss (Germany)
1
papers (2022–2022)
Kym L. Stanley
· Peter MacCallum Cancer Centre
1
papers (2012–2012)
Patrick Metzger
· University of Freiburg
1
papers (2022–2022)
Kelly Waldeck
· The University of Melbourne
1
papers (2012–2012)
—
·
1
papers (2022–2022)
F. Neumann
· Merck KGaA, Darmstadt (Germany)
1
papers (2022–2022)
Michael Bots
· Eindhoven University of Technology
1
papers (2012–2012)
—
·
1
papers (2022–2022)
Rouven Hoefflin
· University of Freiburg
1
papers (2022–2022)
—
·
1
papers (2022–2022)
Gretchen Poortinga
· The University of Melbourne
1
papers (2012–2012)
—
·
1
papers (2022–2022)
Frank T. Zenke
· Merck (Germany)
1
papers (2022–2022)
Melanie Boerries
· University of Freiburg
1
papers (2022–2022)
Richard B. Pearson
· The University of Melbourne
1
papers (2012–2012)
Christian Witt
· Heidelberg University
1
papers (2022–2022)
—
·
1
papers (2022–2022)
—
·
1
papers (2022–2022)